Mammalian Mip/LIN-9 is a cell cycle regulatory protein that is negatively regulated by CDK4/cyclin D. It has been demonstrated that Mip/LIN-9 collaborates with B-Myb during S and G 2 /M in the induction of cyclins A and B, and CDK1. The ortholog of Mip/LIN-9 in Drosophila, Mip130, is part of a large multisubunit protein complex that includes RBF, repressor E2Fs and Myb, in what was termed the dREAM complex. A similar complex, although lacking B-Myb, was also described in Caenorhabditis elegans. Here, we demonstrate that unlike Drosophila, Mip/LIN-9 has mutually exclusive and cell cycle-phasespecific interactions with the mammalian orthologs of the dREAM complex. In G 0 /early G 1 , Mip/LIN-9 forms a complex with E2F4 and p107 or p130, while in late G 1 /S phase, it associates with B-Myb. The separation of Mip/LIN-9 from p107,p130/E2F4 is likely driven by phosphorylation of the pocket proteins by CDK4 since Mip/LIN-9 fails to interact with phosphorylated forms of p107,p130. Importantly, the repressor complex that Mip/LIN-9 forms with p107 takes functional precedence over the transcriptional activation linked to the Mip/LIN-9 and B-Myb interaction since expression of p107 blocks the activation of the cyclin B promoter triggered by B-Myb and Mip/LIN-9.
Introduction
The pocket proteins pRB, p107 and p130 play a central role in the regulation of cell cycle progression (Sherr and Roberts, 2004; Cobrinik, 2005) . The retinoblastoma protein (pRB) was the first member described and it became readily clear that its inactivation via phosphorylation first by cyclin D/cyclin-dependent kinase (CDK)4,6 in mid-G 1 and then by cyclin E/CDK2 in late G 1 was critical to pass the restriction point and commit cells to replicate their DNA and divide (reviewed in Ciemerych and Sicinski, 2005) . The initial inactivation by CDK4 results in derepression of the cyclin E gene, and the consequent increase in cyclin E protein leads to the activation of CDK2, which further inactivates pRB having as a final outcome the transcription of S phase genes (recently reviewed in Sherr and Roberts, 2004; Ciemerych and Sicinski, 2005) . However, the discovery of remaining members of the family, p107 and p130, revealed that G 1 -S progression had additional layers of complexity (recently reviewed in Classon and Dyson, 2001; Classon and Harlow, 2002; Du and Pogoriler, 2006) .
The pocket proteins regulate cell cycle progression by forming complexes that inhibit transcription of specific genes. During G 0 and early G 1 , they form transcriptional repressor complexes with E2F and DP family members to inhibit the expression of genes necessary for the entry into S phase. The E2F family is composed of activating (E2F1-3a) and repressor members (E2F3b, 4-7) . pRB associates primarily with E2F1-3, whereas E2F4-5 preferentially bind p107 or p130 (recently reviewed in Cobrinik, 2005; Dimova and Dyson, 2005) . Interestingly, the combined loss of p107 and p130 deregulates expression of most E2F-responsive genes, whereas the single deletion of pRB deregulates only the p107 and cyclin E genes (Hurford et al., 1997; reviewed in Cobrinik, 2005) . Chromatin immunoprecipitation assays (Chipperfield et al., 1985) further reinforce this concept as pRB can only be detected bound to a few E2F-dependent promoters (that is cyclin E, p107) whereas E2F4,5/p107,p130 complexes occupy the vast majority of E2F-regulated genes studied (Takahashi et al., 2000) . Thus, a model in which p107,p130/E2F4, E2F5 are responsible for the direct promoter repression of E2F target genes, whereas pRB is responsible for the inhibition of activating forms of E2F, seems likely. Once the repression exerted by the pocket proteins is released, activating E2F1-3a/DP1,2 induce transcription of genes required for cell cycle progression.
Importantly, the effect of the pocket proteins and E2Fs in the regulation of cell cycle progression goes beyond G 1 because they can repress transcriptional activation of S and M genes such as cyclins A and B, and CDK1 (Zhu et al., 2004) . Interestingly, transcriptional activation of cyclins A and B, and CDK1 requires not only activating E2Fs, but also the expression of BMyb, which is part of the genes induced in G 1 (Zhu et al., 2004) . It has been recently shown that expression of B-Myb is regulated by Mip/LIN-9 and that both genes function together in the induction of S phase and mitotic genes (Osterloh et al., 2007; Pilkinton et al., 2007) . This requirement for cell cycle progression was partially unexpected since Gagrica et al. (2004) first described that although mammalian Mip/LIN-9 was a collaborator of pRB in the regulation of transformation, it had no effect on cell cycle progression. Interestingly, it was independently reported that mammalian Mip/LIN-9, first named as BARA/LIN-9 (Sandoval et al., 2006) , was inhibited by cyclin D/CDK4 activity as its mutation rescued the CDK4 null phenotype including the cell cycle re-entry defects and the expression of E2F-regulated genes (Sandoval et al., 2006) . Therefore, the current knowledge supports a model in which Mip/LIN-9 acts as a repressor in G 0 /G 1 , which is inactivated by CDK4, and activator of transcription of S/M genes in S phase.
In addition to the mammalian gene, the Mip/LIN-9 family includes Caenorhabditis elegans LIN-9, the first member described (Ferguson and Horvitz, 1989; Beitel et al., 2000) , Drosophila Mip130 and Aly (White-Cooper et al., 1998 Beall et al., 2004; Korenjak et al., 2004; Lewis et al., 2004) and Arabidopsis thaliana Always Early (Bhatt et al., 2004) . Interestingly, Mip130 is part of a large transcriptional repressor complex termed Drosophila RB, E2F and Myb complex (dREAM) because it involves Drosophila RBF, dE2F2 and dm-Myb, the orthologs of mammalian pocket proteins, repressor E2Fs and B-Myb, respectively Korenjak et al., 2004; Lewis et al., 2004) . Additionally, the dREAM complex also includes less well-characterized components such as Mip40 and Mip120 Korenjak et al., 2004; Lewis et al., 2004) . This complex has a negative regulatory role on gene transcription and amplification of specific DNA foci (Beall et al., 2002 Korenjak et al., 2004; Lewis et al., 2004) .
Interestingly, although interactions between pocket proteins, Mip/LIN-9 and B-Myb were also described in mammalian cells (Gagrica et al., 2004; Osterloh et al., 2007; Pilkinton et al., 2007) , the existence of an equivalent of the dREAM complex is uncertain. Moreover, some findings would argue against such a complex. For instance, while in Drosophila the complex is repressive, in mammalian systems, components such as B-Myb are well-known transcriptional activators required for the expression of S and G 2 /M genes (Zhu et al., 2004; Osterloh et al., 2007; Pilkinton et al., 2007) . Second, although Mip/LIN-9, another component of a putative mammalian dREAM complex, is likely to function in G 0 /G 1 as a repressor negatively regulated by cyclin D/CDK4 (Sandoval et al., 2006) , in S phase it regulates the expression of B-Myb and, consequently, B-Myb target genes such as cyclin A, cyclin B and CDK1 (Osterloh et al., 2007; Pilkinton et al., 2007) . Given the importance of a putative mammalian dREAM complex could have in cell cycle regulation, we investigated whether it was also present in mammalian cells. Our results demonstrate that although Mip/LIN-9 was able to interact with p107,p130, E2F4 and B-Myb, it did not associate with the transcriptional repressor complex (p107,p130/E2F4) and B-Myb simultaneously. Moreover, the interactions were cell cycle phase-dependent and the switch of Mip/LIN-9 from the repressor complex in G 0 /G 1 to B-Myb in G 1 /S phase coincided with an increase in CDK4 activity. Therefore, the existence of a complex equivalent to Drosophila dREAM is unlikely in mammalian cells. Importantly, the role of the p107/E2F4 repressor complex takes priority over the activation of S phase and mitotic genes since the expression of p107 blocked the activation of the cyclin B promoter by Mip/LIN-9 and B-Myb.
Results
Mip/LIN-9 interacts with mammalian homologs of the Drosophila dREAM complex: B-Myb, p107, p130 and E2F4 Previous reports indicated that in mammalian cells, Mip/LIN-9 interacts with B-Myb (Osterloh et al., 2007; Pilkinton et al., 2007) and it is pulled down with the pocket proteins (Gagrica et al., 2004; Korenjak et al., 2004; Osterloh et al., 2007) . Yet, the existence of a dREAM complex and its possible role in cell cycle regulation in mammalian cells has not been addressed. To determine whether an interaction between endogenous Mip/LIN-9 and components of a putative mammalian dREAM complex can be detected, we first performed immunoprecipitations with antibodies against p107,p130 and E2F4 followed by western blot with anti-Mip/LIN-9 monoclonal antibody (mAb). Figures 1a and b show that the endogenous 62 and 54 kDa forms of Mip/LIN-9 co-precipitated with the p107 and p130 pocket proteins in human HeLa cells while the 62 kDa protein, the most common form of Mip/LIN-9 expressed in mouse cells (Sandoval et al., 2006) , was pulled down in mouse NIH3T3 cells. A weak interaction between Mip/LIN-9 and E2F4 was detected in asynchronous HeLa but not in NIH3T3 cells. The differences in association observed using endogenous proteins raised the possibility that the structure of the complex could be cell context-dependent or influenced by the cell cycle distribution at the time of cell harvesting. To address this issue, NIH3T3 cells were synchronized in G 0 /G 1 or S phase by serum starvation for 48 h followed by release in growth medium before sample collection for immunoprecipitations/western blot. This approach clearly demonstrated that Mip/ LIN-9 interacts with p107 and p130 in cells synchronized in G 0 /G 1 ( Figure 1c) ; however, the association is significantly weaker when the majority of the cells are in late G 1 and S phase ( Figure 1d ). As expected, very little p130 is detected in S phase (Figure 1d , bottom panel).
The detection of p107 in anti-p130 immunoprecipitates is due to crossreactivity of this particular anti-p130 antibody with p107 in immunoprecipitations but not in immunoblots (compare middle and bottom panels). These experiments also demonstrate that the interactions observed are specific because they can be detected not only in immunoprecipitations with anti-p107 and anti-p130 antibodies, but also in reciprocal assays using anti-Mip/LIN-9 antibodies. Similarly, the association of Mip/LIN-9 and E2F4 is evident in cells that have been synchronized in G 0 /G 1 by starvation (Figure 1e ). Importantly, the experiments performed in HeLa cells also demonstrate that the human papilloma virus protein E7 (Vousden, 1990) does not affect the interaction of Mip/ LIN-9 with the pocket proteins.
We should point out that to our surprise, we have not been able to detect an association between Mip/LIN-9 and pRB as previously reported by Gagrica et al. (2004) , although identical cell lines (that is HeLa cells) and a variety of anti-pRB antibodies were used. This is illustrated in Figure 1f , in which the anti-Mip/LIN-9 mAbdoes not co-precipitate pRB, although this pocket protein is easily detected in immunoprecipitates with the anti-pRB antibody or by an antibody directed against a known partner of pRB such as E2F3 (lanes 4 and 5). The reciprocal experiment, immunoblotting with the anti-Mip/LIN-9 mAb, confirms that no interaction between endogenous pRB or E2F3 and Mip/LIN-9 can be detected, further supporting the concept that Mip/LIN-9 specifically interacts with the repressor complex formed by p107 or p130 and E2F4, but not with pRB or E2F3. Additionally, no interaction with E2F1 or E2F6 has been detected (data not shown). Identical results were obtained using NIH3T3 cells (data not shown). The difference with previous reports may be explained by the fact that the interaction between pRB and Mip/LIN-9 was previously identified using glutathione-S-transferase (GST) fusion proteins or overexpression of both proteins that could detect very weak interactions (Gagrica et al., 2004) . Nevertheless, it is worth mentioning that even if there is a weak interaction with pRB, the stronger association with p130 or p107 supports the concept that most of the biological function of Mip/LIN-9 should be exerted within the context of these pocket proteins. Since there are functional similarities between p107 and p130, for the sake of simplicity we will refer to these proteins as p107,p130, hereafter. ) were used for co-immunoprecipitation of endogenous Mip/LIN-9 and p107,p130 or E2F4 as described in Materials and methods. Immunoprecipitations were performed with specific polyclonal antibodies against Mip/LIN-9, p107,p130 and E2F4 or normal rabbit serum (NR). Total lysate (lysate) was used as control input. Immunoblotting was performed with the anti-Mip/ LIN-9 mAb#6. L and S show the migration of Mip/LIN-9 long (62 kDa) and short (54 kDa), respectively. (c and d) NIH3T3 cells were synchronized in G 0 /G 1 (c and e) and S (d) phases of the cell cycle by serum starvation followed by release in complete growth medium (the percent of cells in each phase of the cell cycle is indicated at the bottom of each panel). Immunoprecipitations ((IP), top of each lane) followed by western blot analysis (WB) were performed with the indicated antibodies. HeLa (f) or SAOS-2 (g) cells were used to assess the interaction of retinoblastoma protein (pRB) or B-Myb, respectively, with Mip/LIN-9. IP/WB were performed as described in the previous panels.
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As expected, Figure 1g shows that Mip/LIN-9 associates with B-Myb (Osterloh et al., 2007; Pilkinton et al., 2007) demonstrating that it can interact with the mammalian homologs of the dREAM complex: p107,p130, E2F4 and B-Myb.
Mip/LIN-9 interacts with E2F4, p107/p130 in G 0 -early G 1 and with B-Myb in late G 1 /S phase Although mammalian Mip/LIN-9 is capable of associating with all the components of the dREAM complex, some findings question the presence of an equivalent complex in mammalian cells. For example, mammalian B-Myb is a well-known transcriptional activator (Saville and Watson, 1998a; Oh and Reddy, 1999; Sala and Watson, 1999; Joaquin and Watson, 2003; Ness, 2003; Zhu et al., 2004) and together with Mip/LIN-9 regulates the expression of S and G 2 /M genes (Osterloh et al., 2007; Pilkinton et al., 2007) , while in Drosophila, Dmmyb is also part of the dREAM repressor complex that regulates cell cycle-independent genes Korenjak et al., 2004; Lewis et al., 2004) . These findings led us to test the hypothesis that different complexes involving elements of the mammalian dREAM complex may be present in distinct phases of the cell cycle. To address this issue, nuclear extracts obtained from NIH3T3 cells synchronized in different stages of the cell cycle were used to study the association of Mip/ LIN-9 with different components of the dREAM complex. Figure 2a shows that p107,p130 and E2F4 specifically interact with Mip/LIN-9 in G 0 and the association rapidly decreases when the cells enter G 1 (4 and 8 h). The reduction in the interaction, at least in the case of p107, cannot be explained by a decrease in its expression as direct immunoblotting (Figure 2b ) demonstrates that the total level of this protein in nuclear lysates augments during G 1 progression (8 and 12 h points). However, the decrease in nuclear E2F4 due to cytoplasmic translocation during G 1 progression can account for the lack of interaction with Mip/LIN-9 (Rayman et al., 2002) . Interestingly, Figure 2a also shows that the separation of Mip/LIN-9 from components of the repressor complex formed by p107 or p130 and E2F4 after cell cycle re-entry is followed by a progressive increase in the association with B-Myb (Figure 2a, 8 and 12 h), and correlates with the initial induction of genes such as cyclin A that are dependent on the interaction between these proteins (Pilkinton et al., 2007) . The association between Mip/LIN-9 and B-Myb decreases once cells enter G 2 /M and becomes almost undetectable when most of the cells have re-entered G 1 (20 h). These results strongly suggest that Mip/LIN-9 does not simultaneously interact with the pocket proteins and B-Myb.
It is worth noting that the experiments described above take into account only the complexes containing Mip/LIN-9, and therefore, it is possible that complexes involving B-Myb, p107,p130 and/or E2F4, but not Mip/ LIN-9, may exist. To address this question, nuclear lysates from the same experiment described in Figure 2a were used for immunoprecipitations with antibodies against p107,p130 and B-Myb followed by immunoblotting with antibodies against the components of the putative mammalian dREAM complex. Figures 3a and b confirm that Mip/LIN-9 is present in p107 or p130 immunoprecipitates from cells that are in G 0 , but the association is almost undetectable in cells that re-entered G 1 (Figures 3a and b, 8, 12 and 16 h) . These results show that Mip/LIN-9 does not interact with the repressor complex formed by p107 or p130 and E2F4 once cells reentered G 1 and does not re-join with this complex until the beginning of the next cycle although E2F4 and p107 begin to re-associate in S and G 2 /M (Figure 3b, 12 and 16 h). Importantly, immunoprecipitations with the anti-B-Myb antibody confirms that B-Myb interacts specifically with Mip/LIN-9 in late G 1 and S phases (Figure 3c , 8 and 12 h). Additionally, no interaction between endogenous p107 or p130 and B-Myb was detected using antibodies against B-Myb or these pocket proteins (Figures 3a-c) . These results suggest that a complex that includes Mip/LIN-9, B-Myb and the pocket proteins does not exist or it is present in such a low abundance that makes its physiological role questionable.
As p107 and p130 are phosphorylated/inactivated by CDK4 and the mutation of Mip/LIN-9 corrected the CDK4 null phenotype by restoring expression of E2F-regulated genes, we investigated whether the increase in CDK4/cyclin D activity coincided with the separation of Mip/LIN-9 from the p107,p130/E2F4 complex. Figure 3d shows that when CDK4 activity is elevated above G 0 levels from mid-G 1 to G 2 (Gabrielli et al., 1999; Burgess et al., 2006) , the association of Mip/LIN-9 with p107,p130 and E2F4 is very low (see Figure 2) . However, once cyclin D expression returns to G 1 levels, the interaction between these pocket proteins and Mip/ LIN-9 is restored. This and other findings suggest that there is little or no interaction between Mip/LIN-9 and phosphorylated pocket proteins. For example, the antiMip/LIN-9 mAb co-precipitates only the hypophosphorylated form of p130 present in cells in G 0 and Figure 2 Interaction of Mip/LIN-9 with mammalian orthologs of the dREAM complex in distinct phases of the cell cycle. Serumstarved NIH3T3 cells were released by the addition of serum, and samples for fluorescent-activated cell sorting analysis and protein studies were collected every 4 h. The cell cycle distribution is shown at the bottom of panel a. Nuclear extracts were used for immunoprecipitations (IP) with the anti-Mip/LIN-9 monoclonal antibody followed by immunoblotting (western blot analysis (WB)) with antibodies against the indicated mammalian orthologs of the dREAM complex proteins. Expression of cell cycle regulatory proteins was assessed by direct analysis of the lysates used in panel a for IP.
Cell cycle-specific interactions of mammalian Mip/LIN-9 M Pilkinton et al early G 1 (Figures 2a and b , compare 0 and 4 h). The appearance of a hyperphosphorylated form of this pocket protein, which is clearly detected in anti-p130 immunoprecipitates (Figure 3a ), coincides with a disappearance of Mip/LIN-9 from the complex ( Figure 3a , 8-h time point). Additionally, very high levels of phosphorylated p107 are detected in nuclear extracts from mid-G 1 to S phase, and yet, Mip/LIN-9 does not interact with this pocket protein but rather with B-Myb. We do not believe that phosphorylation of Mip/LIN-9 by CDK4 plays a role in the disruption of the complex as we have no evidence that this kinase or even CDK2 can phosphorylate Mip/LIN-9 (data not shown). Of note, it is not surprising that the separation of p107,p130 and E2F4 from Mip/LIN-9 begins as soon as the cells re-enter the cell cycle and before the increase in cyclin D-associated CDK4 activity (Figure 3d ), as it has been reported that other cyclin/CDK complexes are responsible for the initial phosphorylation of the pocket proteins that result in the exit from G 0 (Ren and Rollins, 2004 ).
The nuclear localization of Mip/LIN-9 or the interaction with B-Myb is not dependent on p107 and p130
In the absence of pocket proteins, E2F4 is mainly cytoplasmic and there are constitutively high levels of BMyb mRNA (Hurford et al., 1997; Rayman et al., 2002) ; therefore we next asked whether the localization of Mip/ LIN-9 and its interaction with B-Myb would be altered in cells that lack p107 and p130. Figure 4 shows that in p107
À/À 3T3 cells, Mip/LIN-9 and B-Myb remain as nuclear proteins (panel a), whereas the majority of E2F4 is cytoplasmic. Additionally, Mip/LIN-9 and B-Myb interact in the same manner (panel b) as in control 3T3 cells. Moreover, the interaction does not appear to be downregulated in cells that lack the pocket proteins (compare with Figures 4b and a) . These results demonstrate that the localization of Mip/LIN-9 and its association with B-Myb (middle panel) do not depend on the nuclear expression of p107 or p130.
p107 inhibits the activation of the cyclin B promoter produced by Mip/LIN-9 and B-Myb The results presented above indicate that cell cycle progression leads to the ordered transition of Mip/LIN-9 from a repressor complex to the association with B-Myb. They also suggest that an environment in which p107,p130 is either inactivated by phosphorylation or deleted is required for Mip/LIN-9 to functionally interact with B-Myb. As it has been previously demonstrated that the interaction between Mip/LIN-9 and B-Myb is required for the activation of S phase and mitotic genes (Osterloh et al., 2007; Pilkinton et al., 2007) , the inhibitory effect of p107 should take precedence to secure the activation of S phase and mitotic genes at the appropriate time. To address this issue, we determined the effect of p107 on the transcription of a cyclin B-luciferase construct induced by Mip/ LIN-9 and B-Myb (Pilkinton et al., 2007) . Figure 5a shows that the expression of p107 blocks more than 60% of the activation of the cyclin B promoter induced by Mip/LIN-9 and B-Myb. More importantly, increasing amounts of Mip/LIN-9 and B-Myb were unable to overcome the inhibition exerted by p107 (Figure 5b) suggesting that the repressor effect of this pocket protein takes priority over the activation produced by Mip/LIN-9 on B-Myb. Aliquots from the same cell lysates described in Figure 2 were used for immunoprecipitations (IP) with antibodies against p130 (a), p107 (b) or B-Myb (c) followed by western blotting (WB) with the indicated antibodies. (d) Immunocomplex-kinase assay. The same lysates described above were immunoprecipitated with an anti-cyclin D antibody and an immunocomplex-kinase assay was performed using a glutathione-Stransferase-retinoblastoma as a substrate to assess cyclin D-associated kinase activity. The graph represents kinase activity normalized by the background activity obtained by IP with non-immune rabbit serum (NR). Densitometric analysis was performed using the program NIH-Image and expressed as arbitrary units. Figure 4 The interaction between B-Myb and Mip/LIN-9 does not require p107 or p130. Nuclear and cytoplasmic protein extracts obtained from synchronized p107 À/À p130 À/À (PP-DKO) 3T3 cells were used to study the interaction between B-Myb and Mip/LIN-9. Lysates were directly analysed by immunoblotting (a) and immunoprecipitations/western blot analysis (WB) (b) as described in Figures 2 and 3 . WB with antibodies against B23 and tubulin was used to assess the quality of the nuclear and cytoplasmic fractions, respectively.
Discussion
It has been shown that regulation of the cell cycle by the pRB is critical for a coordinated entrance into S phase and progression through mitosis. Imbalances in these mechanisms can lead to unregulated cell proliferation and tumor formation (Sherr and McCormick, 2002; Sherr, 2004) . Interestingly, alterations of regulators of the pocket proteins, and in particular those involved in the early phosphorylation such as amplifications of cyclin D or CDK4, or inactivation of p16, are more common in cancers than mutations of CDK2, cyclin E or CIP/KIP proteins (Sherr, 1996) . This raises the possibility that CDK/cyclin D is responsible not only for the inactivation of pRB, but also other targets. Indeed, CDK4 is also responsible for the inactivation of p107 and p130 and, unlike pRB, there is no evidence that supports a role of CDK2/cyclin E in the inactivation of these pocket proteins (Beijersbergen et al., 1995; Xiao et al., 1996; Leng et al., 2002) .
There is compelling evidence indicating that Mip/ LIN-9 also acts downstream of CDK4. For example, a mutation of Mip/LIN-9 (D84) rescued the defects observed in mice that lack CDK4 (Sandoval et al., 2006) , and in particular, the delayed re-entry into the cell cycle and the expression of E2F-regulated genes. Additionally, the inhibition in S-phase entry produced by the ectopic expression of Mip/LIN-9 was partially blocked by cyclin D. Interestingly, the function of Mip/ LIN-9 was not restricted to G 1 as it is important in later stages of cell cycle for the induction of S phase and mitotic genes. This role is accomplished via an association with B-Myb. The existence of a repressor complex in Drosophila, dREAM, involving not only the pocket proteins and Mip/LIN-9 but also B-Myb suggested that Mip/LIN-9 could be the link between the G 1 and S/M events. Yet, the dual or even opposite roles of Mip/LIN-9 in G 1 and S phase raise an important question: how does Mip/LIN-9 go from being a repressor in G 0 /G 1 (Sandoval et al., 2006) The results presented here address some of these issues. First, a protein complex that simultaneously includes the pocket proteins p107,p130, E2Fs, Mip/ LIN-9 and B-Myb is not detected in mouse or human cells, strongly suggesting that there is no equivalent to Drosophila dREAM in mammalian cells. Second, complexes containing Mip/LIN-9 and the pocket proteins/E2Fs or B-Myb are formed in distinct phases of the cell cycle: in G 0 /G 1 , Mip/LIN-9 associates with the repressor complex formed by p107 or p130 and E2F4, and in S phase, Mip/LIN-9 interacts with B-Myb. Therefore, there is a sequence of events marked by the distinct association of Mip/LIN-9 with the repressor complex in G 0 , its release from this complex as soon as the cell re-enters the cell cycle and the interaction with B-Myb. The latter was previously demonstrated to be critical for the integrity of the B-Myb protein and the induction of cyclin A, cyclin B and CDK1 (Pilkinton et al., 2007) . The interaction between B-Myb and Mip/ LIN-9 does not depend on a previous association with the pocket proteins since it can be detected in cells that lack p107 and p130.
Although Mip/LIN-9 is negatively regulated by CDK4/cyclin D, there is no evidence supporting a mechanism that involves the direct phosphorylation by this CDK (Sandoval et al., 2006) . Therefore, an alternative is that the phosphorylation of p107,p130 by CDK4 would be responsible for the release of Mip/LIN-9 from the repressor complex. Indeed, several lines of evidence support such a mechanism: (i) disengagement of Mip/LIN-9 from p107,p130 and E2F4 begins when p107,p130 becomes phosphorylated and persists as long as the activity of CDK4 is above G 0 levels. (ii) Mip/ LIN-9 does not interact with p107 in late G 1 or S phase when this pocket protein is phosphorylated, although both can be detected in nuclear extracts in high levels (Figures 2 and 3) . (iii) Similarly, Mip/LIN-9 co-immunoprecipitates only with the hypophosphorylated form of p130 (Figure 3) . Importantly, the repression exerted by p107 takes precedence with respect to the activation of the cyclin B promoter produced by Mip/LIN-9 and B-Myb to secure the orderly transition through the distinct phases of the cell cycle. This is demonstrated by the finding that the inhibition of the cyclin B promoter cannot be overridden by transfection of larger amounts of Mip/LIN-9 and BMyb even in cells such as T98G in which the activity of CDK4 is upregulated by mutation of p16. Additionally, our data strongly suggest that the role of Mip/LIN-9 in G 0 /G 1 is exerted only within the context of p107 and Cell cycle-specific interactions of mammalian Mip/LIN-9 M Pilkinton et al p130, and that it is very unlikely that Mip/LIN-9 has a physiologically meaningful interaction with pRB as previously reported by Gagrica et al. (2004) . Given the specificity of Mip/LIN-9 for the p107,p130/E2F4 repressor complex, it is tempting to speculate that CDK4 regulates pathways that lead to inactivation of the pocket proteins in a nonlinear manner as previously proposed by Bruce et al. (2000) . In this model (Figure 6 ), a repressor complex including p107,p130, E2F4 and Mip/LIN-9 responsible for the regulation of the expression of S/M phase genes is disrupted in G 0 /G 1 by CDK4 phosphorylation allowing the switch of Mip/LIN-9 to an association with B-Myb in late G 1 /early S phase that results in the stabilization of this protein (Pilkinton et al., 2007) . B-Myb is then phosphorylated by CDK2/ cyclin A, and possibly CDK2/cyclin E (Robinson et al., 1996; Lane et al., 1997; Sala et al., 1997; Ziebold et al., 1997; Saville and Watson, 1998b; Bartsch et al., 1999; Muller-Tidow et al., 2001; Johnson et al., 2002; Petrovas et al., 2003) , and, in tandem with activating E2Fs (Zhu et al., 2004) , induces transcription of S phase and mitotic genes such as cyclin A, cyclin B and CDK1 (Osterloh et al., 2007; Pilkinton et al., 2007) . The requirement of activating E2Fs for the induction of S/M genes indicates the interdependency and non-redundancy of the pRB and p107,p130 proteins, as inactivation of pRB alone will not allow derepression of S/M genes controlled by p107,p130/E2F4/Mip/LIN-9, whereas the inactivation of p107,p130 would not allow the release of activating E2Fs regulated by pRB. This may explain why mutations that increase the activity of CDK4 (amplification of CDK4 and cyclin D, or mutations of p16) are more common in cancers than mutations of the pRB. It remains to be determined if Mip/LIN-9 also participates in the repression of G 1 /S genes such as DHFR, TK and CDC6, which are also regulated by p107,p130/E2F4,5 ( Figure 6 ) or it is specific for the regulation of genes activated later in the cell cycle such as cyclin A, cyclin B and CDK1 (Osterloh et al., 2007; Pilkinton et al., 2007) .
Materials and methods
Tissue culture, constructs and transfections Cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), glutamine and non-essential amino acids (Pilkinton et al., 2007) .
Immunoprecipitations and immunoblotting
Western blot analysis was performed as described previously (Sandoval et al., 2006) . Antibodies against Mip/LIN-9, mAb and rabbit polyclonal (Gibbs et al., 1994) , were previously described (Sandoval et al., 2006) . The following antibodies were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA, USA): anti-B-Myb (N-19, sc-724); -cyclin B (sc-245), -cyclin A (sc-751), -E2F4 (sc-866) and -E2F3 (sc-879). The anti-CDK1 (610038) and -Rb (554136), and anti-tubulin (ab3194) antibodies were obtained from BD Pharmigen (San Diego, CA, USA) and Abcam (Cambridge, MA, USA).
Cell cycle synchronization NIH3T3 cells were plated at 10 6 per 100 mm dish and 24 h later washed with phosphate-buffered saline and cultured in serumfree DMEM for 48-72 h. Cells were released by changing medium to DMEM supplemented with 10% FBS and then harvested at the indicated post-release time points. Synchronization was assessed by fluorescent-activated cell sorting analysis of propidium iodine-stained cells. Figure 6 Schematic representation of a model postulating the specific regulation of S/M genes by CDK4. As proposed by Bruce et al. (2000) , the pocket protein pathway is shown as a nonlinear pathway downstream of CDK4. The activation of CDK4 has several consequences: (a) the inactivation of p107,p130 that results in derepression of G 1 /S genes, among them B-Myb; (b) the release of Mip/ LIN-9 from the p107,p130 repressor complex; and (c) the initial phosphorylation of retinoblastoma protein (pRB). This model also suggests that the pRB and p107,p130 pathways merge in S phase as the complete inactivation of pRB by CDK2 releases activating E2Fs that together with Mip/LIN-9 and B-Myb are critical for the induction of S/M genes.
In vitro kinase assay An anti-cyclin D antibody was used to immunoprecipitate NIH3T3 nuclear lysates. Immunocomplexes were incubated with 2.5mCi of [g-ATP] and 2 mg of GST-Rb (Santa Cruz, sc-4112) in kinase buffer (50 mM Hepes, pH 7.5, 10 mM MgCl 2 , 1 mM dithiothreitol, 2.5 mM EGTA, 10 mM b-glycerophosphate, 1 mM NaF and 0.1 mM Na 3 VO 4 ) for 30 min. The reaction was quenched by adding 2 Â sample loading buffer. Proteins were resolved by SDS-polyacrylamide gel electrophoresis, transferred to a polyvinylidene difluoride membrane and exposed to film. Densitometric quantitation was made using NIH-IMAGE software.
Promoter assays
The luciferase assay system from Promega (Madison, WI, USA) was used for promoter assays as described previously (Pilkinton et al., 2007) .
